← The Wire
IDXXNasdaq
IDEXX LABORATORIES INC /DE
In Vitro & In Vivo Diagnostic Substances · DE · CIK 874716
IDEXX LABORATORIES INC /DE provides products and services for animal health, water, and livestock/poultry/diagnostics
⚡ Elevated coverage
$44.24B
Market cap
$535.93
Last close
-2.8%
1D
-1.8%
5D
799K
Volume
Price · last 39 sessions-4.8%
May 4L $528.68 · H $579.23Jun 29
181
Total filings
May 15, 2026
Last filing
12/31
Fiscal year end
8-KBylaw Amendment · Shareholder VoteMay 15, 202610-Q10-QMay 5, 20268-KResults of OperationsMay 5, 2026DEFA14ADEFA14AMar 27, 2026DEF 14ADEF 14AMar 27, 20268-KExecutive ChangeMar 26, 202610-K10-KFeb 20, 20268-KExecutive ChangeFeb 13, 20268-KResults of OperationsFeb 2, 20268-KExecutive Change · Reg FD DisclosureJan 13, 20268-KMaterial Agreement · New Debt / ObligationNov 13, 202510-Q10-QNov 3, 20258-KResults of OperationsNov 3, 20258-KExecutive ChangeOct 7, 202510-Q10-QAug 4, 20258-KResults of OperationsAug 4, 20258-KExecutive ChangeJul 10, 20258-KBylaw Amendment · Shareholder VoteMay 9, 202510-Q10-QMay 1, 20258-KResults of OperationsMay 1, 2025DEFA14ADEFA14AMar 28, 2025DEF 14ADEF 14AMar 28, 202510-K10-KFeb 21, 20258-KExecutive ChangeFeb 14, 20258-KResults of OperationsFeb 3, 20258-KExecutive ChangeDec 12, 20248-KCompany UpdateDec 9, 20248-KExecutive Change · Reg FD DisclosureNov 21, 20248-KExecutive ChangeNov 12, 20248-KMaterial AgreementNov 6, 202410-Q10-QOct 31, 20248-K/AResults of OperationsOct 31, 20248-KResults of OperationsOct 31, 202410-Q10-QAug 6, 20248-KResults of OperationsAug 6, 20248-KExecutive Change · Shareholder VoteMay 10, 202410-Q10-QMay 1, 20248-KResults of OperationsMay 1, 2024DEFA14ADEFA14AMar 27, 2024DEF 14ADEF 14AMar 27, 202410-K10-KFeb 22, 20248-KResults of OperationsFeb 5, 20248-KExecutive ChangeDec 7, 202310-Q10-QNov 1, 20238-KResults of OperationsNov 1, 202310-Q10-QAug 1, 20238-KResults of OperationsAug 1, 20238-KExecutive ChangeJul 12, 20238-KShareholder VoteMay 19, 202310-Q10-QMay 2, 20238-KResults of OperationsMay 2, 2023DEFA14ADEFA14AMar 31, 2023DEF 14ADEF 14AMar 31, 202310-K10-KFeb 16, 2023SC 13GSC 13GFeb 14, 2023SC 13GSC 13GFeb 14, 20238-KResults of OperationsFeb 6, 202310-Q10-QNov 1, 20228-KResults of OperationsNov 1, 20228-KMaterial Agreement · New Debt / ObligationOct 21, 202210-Q10-QAug 2, 20228-KResults of OperationsAug 2, 20228-KBylaw AmendmentJul 15, 20228-KReg FD DisclosureJun 14, 20228-KShareholder VoteMay 13, 202210-Q10-QMay 4, 20228-KResults of OperationsMay 4, 2022DEFA14ADEFA14AMar 31, 2022DEF 14ADEF 14AMar 31, 202210-K10-KFeb 16, 20228-KResults of OperationsFeb 2, 20228-KMaterial Agreement · New Debt / ObligationDec 9, 202110-Q10-QNov 2, 20218-KResults of OperationsNov 2, 202110-Q10-QJul 30, 20218-KResults of OperationsJul 30, 20218-KShareholder VoteMay 18, 202110-Q10-QMay 4, 20218-KResults of OperationsMay 4, 2021DEFA14ADEFA14AMar 31, 2021
Insider Activity
In the 90 days to Mar 3, 2026: 5 sold $29.9M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 3, 2026 | Hunt NimrataExecutive Vice President | Sell | 1,758 | $634.57 | $1.1M |
| Feb 26, 2026 | Mazelsky Jonathan JayPresident and CEO | Sell | 3,660 | $658.92 | $2.4M |
| Feb 26, 2026 | Mazelsky Jonathan JayPresident and CEO | Sell | 2,859 | $659.75 | $1.9M |
| Feb 26, 2026 | Mazelsky Jonathan JayPresident and CEO | Sell | 2,860 | $657.84 | $1.9M |
| Feb 26, 2026 | Hunt NimrataExecutive Vice President | Sell | 2,693 | $661.54 | $1.8M |
| Feb 26, 2026 | Mazelsky Jonathan JayPresident and CEO | Sell | 2,589 | $663.04 | $1.7M |
| Feb 26, 2026 | Mazelsky Jonathan JayPresident and CEO | Sell | 1,669 | $652.49 | $1.1M |
| Feb 26, 2026 | Mazelsky Jonathan JayPresident and CEO | Sell | 1,488 | $655.85 | $976K |
| Feb 26, 2026 | Mazelsky Jonathan JayPresident and CEO | Sell | 1,343 | $656.85 | $882K |
| Feb 26, 2026 | Mazelsky Jonathan JayPresident and CEO | Sell | 1,281 | $650.67 | $834K |
| Feb 26, 2026 | Mazelsky Jonathan JayPresident and CEO | Sell | 1,200 | $661.10 | $793K |
| Feb 26, 2026 | Mazelsky Jonathan JayPresident and CEO | Sell | 1,171 | $653.68 | $765K |
| Feb 26, 2026 | Mazelsky Jonathan JayPresident and CEO | Sell | 1,111 | $654.63 | $727K |
| Feb 26, 2026 | Mazelsky Jonathan JayPresident and CEO | Sell | 1,095 | $651.49 | $713K |
| Feb 26, 2026 | Mazelsky Jonathan JayPresident and CEO | Sell | 1,000 | $662.16 | $662K |
| Feb 17, 2026 | Erickson Michael GExecutive Vice President | Sell | 2,694 | $628.22 | $1.7M |
| Feb 17, 2026 | Erickson Michael GExecutive Vice President | Sell | 1,288 | $626.26 | $807K |
| Feb 17, 2026 | Vandebroek Sophie V.Director | Sell | 945 | $628.65 | $594K |
| Feb 17, 2026 | Erickson Michael GExecutive Vice President | Sell | 689 | $629.09 | $433K |
| Feb 17, 2026 | Vandebroek Sophie V.Director | Sell | 519 | $628.56 | $326K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 6 reputable articles.
MarketWatchIDEXX Laboratories Inc. stock underperforms Monday when compared to competitors7d agoMarketWatchIDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors13d agoMarketWatchIDEXX Laboratories Inc. stock rises Monday, still underperforms market14d agoMarketWatchIDEXX Laboratories Inc. stock outperforms competitors on strong trading day20d agoMarketWatchIDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors27d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance